Jay Brad­ner joins Am­gen to lead R&D as David Reese moves to new chief tech­nol­o­gy of­fi­cer role

Last year
People
R&D

Gro­cery de­liv­ery gi­ant In­stacart is bet­ting that food as med­i­cine pro­grams will help grow its busi­ness

Last year
Health Tech

For­mer ex­ecs from Pfiz­er obe­si­ty drug pro­gram have start­ed a new biotech with $52M from VC fund ATP

Last year
Financing
Startups

Up­dat­ed: Meta­bol­ic drug de­vel­op­er High­T­ide Ther­a­peu­tics eyes $36M raise with HK IPO

Last year
Financing

Head­ed to San Fran­cis­co? Here’s how you can cus­tomize your ex­pe­ri­ence at #JPM24 with End­points News

Last year
Bioregnum
R&D

Pathos AI makes suc­cess­ful takeover bid for Rain On­col­o­gy

Last year
Deals

White House keeps fo­cus on low­er­ing drug prices, turns Re­gen­eron's con­tract lan­guage in­to new stan­dard

Last year
Pharma
FDA+

FDA puts three CARs­gen CAR-T ther­a­pies on clin­i­cal hold, in­clud­ing Mod­er­na-part­nered pro­gram

Last year
Cell/Gene Tx
FDA+

Mod­er­na, Mer­ck un­veil three-year mid-stage da­ta for vac­cine-Keytru­da com­bo in melanoma, with PhI­II un­der­way

Last year
R&D

MIT spin­out aims to im­prove man­u­fac­tur­ing of pep­tides 

Last year
Manufacturing

Ex­clu­sive: Renowned im­munol­o­gy leader 'Skip' Vir­gin is out as Al­tos Labs med­ical chief

Last year
People

Dig­i­tal health start­up Ro now pre­scribes re­cent­ly ap­proved weight loss drug Zep­bound

Last year
Health Tech

Vir down­sizes by 12%, will close St. Louis and Port­land sites in 2024 to save $40M+ an­nu­al­ly

Last year
People

Pfiz­er’s para­dox: Al­bert Bourla walks a fine line as he tries to turn around 2023's worst-per­form­ing big drug­mak­er

Last year
Pharma

PwC pre­dicts ac­tive 2024 for phar­ma deals as M&A val­ue climbs

Last year
Pharma

Sanofi’s Mourenx pro­duc­tion site leaked a po­ten­tial­ly can­cer­ous neu­ro­tox­in for the sec­ond time 

Last year
Pharma
Manufacturing

As phar­mas dou­ble down on dig­i­tal and AI, tal­ent is a key con­sid­er­a­tion, con­sul­tant says

Last year
Pharma
Marketing

Sen­ate health com­mit­tee ad­vances changes to how FDA would ap­prove new opi­oids

Last year
FDA+
Law

Supreme Court to re­view lim­i­ta­tions on abor­tion pill

Last year
Pharma
Law

Ex­cite­ment over sick­le cell now shifts to long slog of de­liv­er­ing treat­ments, in piv­otal year for blue­bird and gene ...

Last year
Pharma
Cell/Gene Tx

Sofinno­va de­tails Eu­ro­pean in­vest­ment strat­e­gy; C4's new PhI da­ta; Coya clos­es $26M place­ment

Last year
News Briefing

Ed­i­tas Med­i­cine pads run­way with $50M up­front from Ver­tex for Cas9 li­cense

Last year
Deals
Cell/Gene Tx

En­cellin rais­es about $10M for type 1 di­a­betes cell re­place­ment ther­a­py

Last year
Financing

Pfiz­er plans an­oth­er $500M in cost cuts, ex­pects $3.1B in rev­enue from Seagen in 2024

Last year
Pharma
First page Previous page 230231232233234235236 Next page Last page
A service from the Financial Times